Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Ahmad S, He Q, Williams KP, Scott JE. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach. SLAS Discov. 2020 09; 25(8):923-938.
-
Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, Reimer C, Bartek J, Lau A, O'Connor MJ. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Res. 2019 07 15; 79(14):3762-3775.
-
Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009 Jul 13; 169(13):1224-32.
-
Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009 Jun; 63(6):1244-50.
-
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dub? MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.
-
Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):193-200.
-
Brown JD, Kangwanprasert M, Tice A, Melish J. Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection. Hawaii Med J. 2007 Mar; 66(3):60, 62-3.
-
Liang XJ, Yin JJ, Zhou JW, Wang PC, Taylor B, Cardarelli C, Kozar M, Forte R, Aszalos A, Gottesman MM. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Exp Cell Res. 2004 Feb 15; 293(2):283-91.
-
Senseman DM, Salzberg BM. Electrical activity in an exocrine gland: optical recording with a potentiometric dye. Science. 1980 Jun 13; 208(4449):1269-71.